Skip to main content
. 2019 Aug 22;8(13):6064–6081. doi: 10.1002/cam4.2494

Figure 7.

Figure 7

JAK1 and JAK3 were direct target genes of miR‐635. A, Potential binding site of miR‐635 in 3′UTR of JAK1 or JAK3. The mutants were also shown. Detection of miR‐635 mimics on activity of wild‐type or mutant 3′UTR of JAK1 and JAK3 by dual‐luciferase reporter assay. ***P < .001. B, Detection of miR‐635 mimics or inhibitors on expression of miR‐635 by qRT‐PCR, respectively. ***P < .001. C, Detection of miR‐635 mimics or inhibitors on expression of JAK1, JAK3, p‐JAK1, p‐JAK3, STAT3, p‐STAT3, TIMP‐1, and Pim‐1 by western blot. *, **, ***P < .05, P < .01, P < .001. D, Detection of JAK1 or JAK3 overexpression (JAK1 or JAK3) on the mRNA expression of JAK1 or JAK3 by qRT‐PCR. ***P < .001. E, Detection of JAK1 or JAK3 on the protein expression of JAK1 or JAK3 by western blot. ***P < .001. F, Detection of miR‐635 mimics and JAK1 or JAK3 on expression of JAK1, JAK3, p‐JAK1, p‐JAK3, STAT3, p‐STAT3, TIMP‐1, and Pim‐1. **, ***P < .01, P < .001. JAK, Janus kinase; PCR, polymerase chain reaction; Pim‐1, proto‐oncogene serine/threonine‐protein kinase; STAT, signal transducer and activator of transcription protein; TIMP‐1, tissue inhibitor of metalloproteinases